Nate Edwards of Arya Consulting moderates a discussion with Elisabeth Gardiner of Tevard Biosciences and Donny Xu of the RTW Institute about the regulatory and manufacturing hurdles facing rare disease drug developers.
Nathan Edwards, PhD
Advertisement
Nathan Edwards, PhD, is engagement manager with ARYA Consulting Partners. Edwards specializes in business development, new product planning, and early brand strategy. He helps companies lay the foundation for successful launches through data-backed strategies spanning indication assessment to portfolio strategy. With a strong background in pricing and market access, Edwards integrates both commercial and access insights into early asset development to maximize market opportunity.
Articles by Nathan Edwards, PhD
Nathan Edwards of Arya Consulting moderates a discussion with Elisabeth Gardiner of Tevard Biosciences and Donny Xu of the RTW Institute about rare disease treatment development and navigating the FDA’s Rare Pediatric Disease Priority Review Voucher Program.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on BioPharm International
1
Shilpa CDMO Commits $50 Million to Scale Peptide Capacity in India
2
Lonza to Acquire Merck KGaA’s US CDMO Business, Adding ADC, Viral Vector, and LNP Capacity
3
FDA Finalizes Potency Assurance Guidance for Cell and Gene Therapies
4
Teva Licenses US Rights to Samsung Bioepis TNF Inhibitor Biosimilars
5